CardiaTec, a Cambridge University spinout is applying artificial intelligence on large-scale multiomic data to develop the next generation of cardiovascular disease drug targets. The company is specialized in cardiovascular disease (CVD), first focusing on coronary artery disease (CAD).
CardiaTec is developing a target discovery platform leveraging AI to make sense of large-scale multiomic cardiovascular data. As opposed to conventional singular omic analysis, CardiaTec’s proprietary platform unravels relationships that span across every level of biology, from gene variation, methylation and expression, to their connection to proteomic and metabolomic functions to best understand disease development.
Driven through new found understanding of disease biology, CardiaTec is exploring Target-Drug interactions to deliver new treatments to patients faster, cheaper and with a reduced risk of failure. CardiaTec’s ultimate goal is to help reduce the global burden caused by cardiovascular diseases, which continue as the world’s leading global cause of death, claiming over 17 million lives each year.
CardiaTec is developing a target discovery platform leveraging AI to make sense of large-scale multiomic cardiovascular data. As opposed to conventional singular omic analysis, CardiaTec’s proprietary platform unravels relationships that span across every level of biology, from gene variation, methylation and expression, to their connection to proteomic and metabolomic functions to best understand disease development.
Driven through new found understanding of disease biology, CardiaTec is exploring Target-Drug interactions to deliver new treatments to patients faster, cheaper and with a reduced risk of failure. CardiaTec’s ultimate goal is to help reduce the global burden caused by cardiovascular diseases, which continue as the world’s leading global cause of death, claiming over 17 million lives each year.
Total raised: $8.18M
Founders name: Raphael Peralta; Thelma Zablocki; Namshik Han
Investors 2
| Date | Name | Website |
| - | o2h ventur... | o2hventure... |
| 22.07.2022 | Cambridge ... | cambridgea... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 11.09.2024 | Seed | $6.5M | - |
| 07.07.2022 | Pre-Seed | $1.68M | - |
Persons 5
| Date | First Name | Last Name | Title | Location | |||
| - | WooChang | Hwang | Senior Mac... | linkedin.c... | - | w****g@car... | - |
| - | Meabh | MacMahon, ... | Senior Dat... | linkedin.c... | - | m*******n@... | - |
| - | Raphael | Peralta | Co-Founder... | linkedin.c... | - | r******a@c... | - |
| - | Thelma | Zablocki | Co-Founder... | linkedin.c... | - | t*******i@... | - |
| - | Namshik | Han | Co-Founder... | linkedin.c... | - | n**n@cardi... | - |
Mentions in press and media 8
| Date | Title | Description |
| 11.09.2024 | CardiaTec Raises $6.5M in Seed Funding | CardiaTec co-founders Prof. Namshik Han (CTO), Thelma Zablocki (COO), and Raphael Peralta (CEO). CardiaTec, a Cambridge, England, UK-based TechBio company employing computational methods to decode the biology behind cardiovascular disease, ... |
| 10.09.2024 | CardiaTec: Pioneering the Future of Cardiovascular Drug Discovery | In the heart of Cambridge, a new wave of innovation is rising. CardiaTec, a techbio company, has secured $6.5 million in seed funding to tackle one of the world’s most pressing health crises: cardiovascular disease. This funding, led by Mon... |
| 10.09.2024 | CardiaTec raises $6.5M Seed for cardiovascular drug discovery | CardiaTec, a techbio company decoding the biology behind cardiovascular disease, today announces securing $6.5m in seed funding. The new funds will allow CardiaTec to expand its platform and progress proprietary drug targets to the preclini... |
| 10.09.2024 | CardiaTec Secures $6.5M Seed Funding to Advance Its Multi-omics Drug Discovery Platform for Cardiovascular Diseases | CardiaTec co-founders Prof. Namshik Han (CTO), Thelma Zablocki (COO), and Raphael Peralta (CEO). CardiaTec, a TechBio company employing computational methods to decode the biology behind cardiovascular disease, has raised $6.5M in seed fund... |
| 10.09.2024 | Cambridge-based CardiaTec raises €5.8 million for computational cardiovascular drug discovery platform | CardiaTec, a techbio company decoding the biology behind cardiovascular disease, today announces securing €5.8 million in seed funding. The new funds will allow CardiaTec to expand its platform and progress proprietary drug targets to the p... |
| 07.02.2023 | #21toWatch announces shortlist of next generation of Cambridge game-changers set for future success | cofinitive have announced the shortlist for #21toWatch 2023 which this year contains an eclectic mix of industries – biotech, cleantech, agritech, construction, automotive, deep learning, marine, life sciences, AI – all sharing the same mis... |
| 06.07.2022 | Cambridge’s CardiaTec gets €1.6M to tackle cardiovascular diseases using AI; here’s how | CardiaTec, a Cambridge-based firm developing an AI platform to discover drugs for cardiovascular diseases, announced on Wednesday that it has raised £1.4M (approximately €1.6M) in a Pre-Seed round of funding. The round was led by Laidlaw Sc... |
| - | CardiaTec Biosciences | “CardiaTec Biosciences” |